Summary of Study ST001495
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001013. The data can be accessed directly via it's Project DOI: 10.21228/M8RH7J This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
Study ID | ST001495 |
Study Title | Effects of Synbiotic Administration on Fecal Microbiome and Metabolomic Profiles of Dogs receiving Antibiotics |
Study Type | untargeted metabolomics |
Study Summary | Effect of antibiotics on fecal microbiome and metabolome |
Institute | University of California, Davis |
Department | College of Biological Sciences |
Laboratory | West Coast Metabolomics Center |
Last Name | Paglia |
First Name | Kelly |
Address | 451 Health Sciences Drive, Room 1313 |
kpaglia@ucdavis.edu | |
Phone | 5307528129 |
Submit Date | 2020-09-24 |
Raw Data Available | Yes |
Raw Data File Type(s) | cdf |
Analysis Type Detail | GC-MS |
Release Date | 2020-10-13 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
Project ID: | PR001013 |
Project DOI: | doi: 10.21228/M8RH7J |
Project Title: | Effects of Synbiotic Administration on Fecal Microbiome and Metabolomic Profiles of Dogs receiving Antibiotics |
Project Type: | Double-blind randomized controlled trial |
Project Summary: | The purpose of this study was to compare the fecal microbiome and metabolome of dogs administered enrofloxacin and metronidazole, followed by either a placebo or a bacterial/yeast synbiotic combination, for 21 days with reevaluation 8 weeks after treatment. Fecal samples were collected on days 5-7 (baseline), 26-28, and 82-84. The fecal microbiome was analyzed by qPCR and sequencing of 16S rRNA genes; time-of-flight mass spectrometry was used to determine metabolomic profiles. Split plot repeated measures ANOVAs were used to compare results between treatment groups. P < 0.05 was considered significant, with Benjamini & Hochberg’s False Discovery Rate used to adjust for multiple comparisons. Alpha diversity metrics differed significantly over time in both treatment groups, with incomplete recovery by days 82-84. Beta diversity and the dysbiosis index differed significantly over time and between treatment groups, with incomplete recovery at days 82-84 for dogs in the placebo group. Significant group-by-time interactions were noted for 15 genera, including Adlercreutzia, Bifidobacterium, Slackia, Turicibacter, Clostridium, [Ruminococcus], Erysipelotrichaceae_g_, [Eubacterium], and Succinivibrionaceae_g_. Group and time effects were present for six genera, including Collinsella, Ruminococcaceae_g_, and Prevotella. Metabolite profiles differed significantly by group-by-time, group, and time for 28, 20, and 192 metabolites, respectively. These included short-chain fatty acid, bile acid, tryptophan, sphingolipid, benzoic acid, and cinnaminic acid metabolites, as well as fucose and ethanolamine. Changes in many taxa and metabolites persisted through days 82-84. |
Institute: | University of Tennessee |
Department: | College of Veterinary Medicine |
Laboratory: | Small Animal Clinical Sciences |
Last Name: | Whittemore |
First Name: | Jacqueline |
Address: | 2407 River Drive, Knoxville TN 37996 |
Email: | jwhittemore@utk.edu |
Phone: | 865-974-8387 |
Funding Source: | Nutramax Laboratories Veterinary Sciences, Inc., Lancaster, SC |
Subject:
Subject ID: | SU001569 |
Subject Type: | Mammal |
Subject Species: | Canis lupus familiaris |
Taxonomy ID: | 9615 |
Species Group: | Mammals |
Factors:
Subject type: Mammal; Subject species: Canis lupus familiaris (Factor headings shown in green)
mb_sample_id | local_sample_id | Treatment |
---|---|---|
SA125950 | Re_1_006 | Placebo |
SA125951 | Re_2_030 | Placebo |
SA125952 | Sar_1_011 | Placebo |
SA125953 | Ra_3_053 | Placebo |
SA125954 | Ra_2_029 | Placebo |
SA125955 | Lu_3_055 | Placebo |
SA125956 | Ra_1_005 | Placebo |
SA125957 | Sar_2_035 | Placebo |
SA125958 | Sy_1_003 | Placebo |
SA125959 | Ty_2_038 | Placebo |
SA125960 | Ty_3_062 | Placebo |
SA125961 | Bi_1_023 | Placebo |
SA125962 | Ty_1_014 | Placebo |
SA125963 | Sy_3_051 | Placebo |
SA125964 | Lu_2_031 | Placebo |
SA125965 | Sy_2_027 | Placebo |
SA125966 | Sar_3_059 | Placebo |
SA125967 | Re_3_054 | Placebo |
SA125968 | Cu_1_008 | Placebo |
SA125969 | Cu_2_032 | Placebo |
SA125970 | Cu_3_056 | Placebo |
SA125971 | Ca_3_064 | Placebo |
SA125972 | Ca_2_040 | Placebo |
SA125973 | Bi_2_047 | Placebo |
SA125974 | Lu_1_007 | Placebo |
SA125975 | Ca_1_016 | Placebo |
SA125976 | Gu_1_012 | Placebo |
SA125977 | Bi_3_071 | Placebo |
SA125978 | Ki_1_019 | Placebo |
SA125979 | Ki_3_067 | Placebo |
SA125980 | Gu_2_036 | Placebo |
SA125981 | Ji_3_058 | Placebo |
SA125982 | Ki_2_043 | Placebo |
SA125983 | Ji_2_034 | Placebo |
SA125984 | Gu_3_060 | Placebo |
SA125985 | Ji_1_010 | Placebo |
SA125986 | Po_1_018 | Synbiotic |
SA125987 | Po_3_066 | Synbiotic |
SA125988 | Po_2_042 | Synbiotic |
SA125989 | Pa_2_033 | Synbiotic |
SA125990 | Ro_1_004 | Synbiotic |
SA125991 | Ma_3_050 | Synbiotic |
SA125992 | Pa_1_009 | Synbiotic |
SA125993 | Pa_3_057 | Synbiotic |
SA125994 | Sak_3_069 | Synbiotic |
SA125995 | To_2_044 | Synbiotic |
SA125996 | To_3_068 | Synbiotic |
SA125997 | Ma_2_026 | Synbiotic |
SA125998 | To_1_020 | Synbiotic |
SA125999 | Sak_2_045 | Synbiotic |
SA126000 | Ro_3_052 | Synbiotic |
SA126001 | Sak_1_021 | Synbiotic |
SA126002 | Ro_2_028 | Synbiotic |
SA126003 | Al_1_013 | Synbiotic |
SA126004 | Fr_1_022 | Synbiotic |
SA126005 | Fr_2_046 | Synbiotic |
SA126006 | Fr_3_070 | Synbiotic |
SA126007 | Bo_3_065 | Synbiotic |
SA126008 | Bo_2_041 | Synbiotic |
SA126009 | Al_2_037 | Synbiotic |
SA126010 | Al_3_061 | Synbiotic |
SA126011 | Bo_1_017 | Synbiotic |
SA126012 | Gi_1_015 | Synbiotic |
SA126013 | Gi_2_039 | Synbiotic |
SA126014 | Ja_1_024 | Synbiotic |
SA126015 | Ja_2_048 | Synbiotic |
SA126016 | Ja_3_072 | Synbiotic |
SA126017 | Go_3_049 | Synbiotic |
SA126018 | Go_2_025 | Synbiotic |
SA126019 | Gi_3_063 | Synbiotic |
SA126020 | Go_1_001 | Synbiotic |
SA126021 | Ma_1_002 | Synbiotic |
Showing results 1 to 72 of 72 |
Collection:
Collection ID: | CO001564 |
Collection Summary: | Lyophilized feces |
Sample Type: | feces |
Treatment:
Treatment ID: | TR001584 |
Treatment Summary: | 2, 36, Synbiotic, Placebo |
Sample Preparation:
Sampleprep ID: | SP001577 |
Sampleprep Summary: | Dog, Feces, 72, 10-30 mg, Lyophilized feces |
Combined analysis:
Analysis ID | AN002478 |
---|---|
Analysis type | MS |
Chromatography type | GC |
Chromatography system | LECO Pegasus IV GC-time of flight mass spectrometers |
Column | Restek Rtx-5Sil (30m x 0.25mm,0.25um) |
MS Type | EI |
MS instrument type | GC-TOF |
MS instrument name | Leco Pegasus IV TOF |
Ion Mode | POSITIVE |
Units | normalized peak height |
Chromatography:
Chromatography ID: | CH001815 |
Chromatography Summary: | Primary metabolism by GCTOF |
Instrument Name: | LECO Pegasus IV GC-time of flight mass spectrometers |
Column Name: | Restek Rtx-5Sil (30m x 0.25mm,0.25um) |
Chromatography Type: | GC |
MS:
MS ID: | MS002298 |
Analysis ID: | AN002478 |
Instrument Name: | Leco Pegasus IV TOF |
Instrument Type: | GC-TOF |
MS Type: | EI |
MS Comments: | A Leco Pegasus IV time of flight mass spectrometer is controlled by the Leco ChromaTOF software vs. 2.32 (St. Joseph, MI). The transfer line temperature between gas chromatograph and mass spectrometer is set to 280°C. Electron impact ionization at 70V is employed with an ion source temperature of 250°C. Acquisition rate is 17 spectra/second, with a scan mass range of 85-500 Da. |
Ion Mode: | POSITIVE |